INTRACRANIAL DISSEMINATION OF A MACROPROLACTINOMA

被引:25
作者
ASSIES, J
VERHOEFF, NPLG
BOSCH, DA
HOFLAND, LJ
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,DEPT PSYCHIAT,1105 AZ AMSTERDAM,NETHERLANDS
[2] UNIV AMSTERDAM,ACAD MED CTR,DEPT NUCL MED,1105 AZ AMSTERDAM,NETHERLANDS
[3] UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROSURG,1105 AZ AMSTERDAM,NETHERLANDS
[4] ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 3,ROTTERDAM,NETHERLANDS
关键词
D O I
10.1111/j.1365-2265.1993.tb00351.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. I-123-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with In-111-SMS, somatostatin treatment was added to the CV 205-502.
引用
收藏
页码:539 / 546
页数:8
相关论文
共 34 条
[1]   PROLACTIN IN HUMAN CEREBROSPINAL-FLUID [J].
ASSIES, J ;
SCHELLEKENS, APM ;
TOUBER, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1978, 46 (04) :576-586
[2]  
ATIENZA DM, 1991, CANCER, V68, P1605, DOI 10.1002/1097-0142(19911001)68:7<1605::AID-CNCR2820680723>3.0.CO
[3]  
2-D
[4]   STUDIES OF 2 THYROTROPHIN-SECRETING PITUITARY-ADENOMAS - EVIDENCE FOR DOPAMINE RECEPTOR DEFICIENCY [J].
BEVAN, JS ;
BURKE, CW ;
ESIRI, MM ;
ADAMS, CBT ;
BALLABIO, M ;
NISSIM, M ;
FAGLIA, G .
CLINICAL ENDOCRINOLOGY, 1989, 31 (01) :59-70
[5]   NONFUNCTIONING PITUITARY-ADENOMAS DO NOT REGRESS DURING BROMOCRIPTINE THERAPY BUT POSSESS MEMBRANE-BOUND DOPAMINE-RECEPTORS WHICH BIND BROMOCRIPTINE [J].
BEVAN, JS ;
BURKE, CW .
CLINICAL ENDOCRINOLOGY, 1986, 25 (05) :561-572
[6]   DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].
BEVAN, JS ;
WEBSTER, J ;
BURKE, CW ;
SCANLON, MF .
ENDOCRINE REVIEWS, 1992, 13 (02) :220-240
[7]   EFFECTS OF THE DOPAMINE AGONIST CV 205-502 IN HUMAN PROLACTINOMAS RESISTANT TO BROMOCRIPTINE [J].
BRUE, T ;
PELLEGRINI, I ;
GUNZ, G ;
MORANGE, I ;
DEWAILLY, D ;
BROWNELL, J ;
ENJALBERT, A ;
JAQUET, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) :577-584
[8]  
EKBOM K, 1983, ACTA PSYCHIAT NEUROL, V13, P227
[9]   INVIVO DETECTION OF SOMATOSTATIN RECEPTORS IN PATIENTS WITH FUNCTIONLESS PITUITARY-ADENOMAS BY MEANS OF A RADIOIODINATED ANALOG OF SOMATOSTATIN ([I-123]SDZ 204-090) [J].
FAGLIA, G ;
BAZZONI, N ;
SPADA, A ;
AROSIO, M ;
AMBROSI, B ;
SPINELLI, F ;
SARA, R ;
BONINO, C ;
LUNGHI, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :850-856
[10]   MULTIPLE INTRACRANIAL METASTASES FROM A PROLACTIN SECRETING PITUITARY-TUMOR [J].
GASSER, RW ;
FINKENSTEDT, G ;
SKRABAL, F ;
TWERDY, K ;
GRUNERT, V ;
MAYR, U ;
FROMMHOLD, H ;
NEDDEN, DZ ;
FEICHTINGER, J ;
HOFSTAEDTER, F .
CLINICAL ENDOCRINOLOGY, 1985, 22 (01) :17-27